摘要
目的观察布洛芬治疗极低出生体重早产儿动脉导管未闭(PDA)的临床疗效及安全性。方法 46例PDA早产患儿随机分为观察组和对照组各23例,对照组给予吲哚美辛口服,首剂0.2mg/kg,后改为0.1mg/kg,每次间隔12h,共用药3次;观察组给予布洛芬混悬液口服,首剂10mg/kg,在24h和48h后分别给予5mg/kg;比较两组患儿的疗效及不良反应。结果观察组患儿的总有效率为95.7%,对照组为91.3%,两组比较差异无统计学意义(χ2=0.357,P>0.05);两组治疗过程中均有不良反应发生,观察组少尿、肾功能异常的发生率显著低于对照组(P<0.05),而胃肠道反应、脑室内出血等的发生率差异无统计学意义(P>0.05)。结论布洛芬治疗极低出生体重早产儿动脉导管未闭的具有良好的疗效,且不良反应少,安全性好,值得在临床推广使用。
Objective To observe the clinical efficacy of ibuprofen in the treawnent of patent ductus arterio- sus （PDA） in very low birth weight premature infants. Methods Forty-six premature infants were randomly divided into the study group and the control group, with 23 cases in each group. Patients in the control group were treated with indometacin 0.2 mg/kg and then 0.1 mg/kg twice at an interval of 12 h. Patients in the study group was given ibupro- fen suspension 10 mg/kg and then 5 mg/kg after 24 h and 48 h. The clinical efficacy and adverse reactions were com- pared between the two groups. Results The total effective rate was 95.7% in the study group and 91.3% in the con- trol group, with no statistically significant difference between the two groups （%2=0.357, P〉0.05）. The incidences of ol- iguria and renal dysfunction in the study group were significantly lower than those in the control group （P〈0.05）. The incidences of gastrointestinal side effects and intraventricular hemorrhage showed no statistically significant differ- ence between the two groups （P〉0.05）. Conclusion The clinical efficacy of ibuprofen in the treatment of PDA in very low birth weight premature infants is satisfactory and safe, which is worthy of extension in clinical practice.
出处
《海南医学》
CAS
2013年第2期202-204,共3页
Hainan Medical Journal
关键词
动脉导管未闭
布洛芬
极低体重
早产儿
Patent ductus arteriosus
Ibuprofen
Very low birth weight
premature infants
